top of page

Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week for its first-in-class orexin agonist for treating narcolepsy type 1 | 09/12/25

TOP VIDEO: Takeda's CEO Christophe Weber describes the company's landmark phase 3 data on its first-in-class orexin agonist for treating narcolepsy type 1 | 09/12/25

Quick Takes

Upcoming Events

September 16 - Pareto Securities' 15th Annual Healthcare Conference | Stockholm, Sweden

October 7 - Align Summit | Boston, MA

November 3-5 - BIO-Europe 2025 | Vienna, Austria

November 7-9 - SITC Annual Meeting | National Harbour, MD

December 5-9 - ASH Annual Meeting | Orlando, FL

Science Spotlight
with Chloe Kirk

9/16/25 - Broadcasting from Stockholm, Sweden at the Pareto Securities' 16th Annual Healthcare Conference.

9/11/25 - Merck has dealt a blow to UK life sciences by scrapping plans to open a new R&D center in the Kings Cross area of London.

9/11/25 - Ginkgo Bioworks is offering $60K in a competition to anyone who can help it build AI models to predict key properties of antibody drugs..

Latest Videos

Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region | 09/16/25

From Stockholm:

Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch

09/16/2025

Austin Barrett Savills

Savills Life Sciences:
Helping biotech and pharma companies make the most of their real estate footprint.

Sponsored

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to user in the next generation of acid reflux medicines with, linaprazan glurate, a potassium-competitive acid blocker (P-CAB) | 09/16/25

From Stockholm:

Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a P-CAB

09/16/2025

Pareto Securities' Healthcare Conference: Saniona has built expertise in the ion channel space, in addition to its own work, it has partnerships with Jazz, Acadia, and others | 09/16/25

From Stockholm:

Saniona has built expertise in the ion channel space. In addition to its own work, it has partnerships with Jazz, Acadia, and others

09/16/2025

Pareto Securities' Healthcare Conference: BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program | 09/16/25

From Stockholm:

BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program

09/16//2025

Shows

Around Kendall Square

What's new at BiotechTV - from our founder

SF Healthcare Week: Nicole Paulk shares an update on her company Siren Biotechnology and describes what the environment is like for smaller companies in biotech right now | 01/16/25

09:50

SF Healthcare Week: Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets | 01/15/25

12:06

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, BCMA, and lupus programs | 01/15/25

11:05

SF Healthcare Week: Affinity Asset Advisors' Head of Research Patrick Nosker shares his take on Monday's conference news, and discusses some of his fund's top holdings | 01/13/25

09:45

SF Healthcare Week: The CEO of Arvians talks protein degradation, including about the industry's first phase 3 readout that is upcoming | 01/15/25

11:42

SF Healthcare Week: Cytokinetics CEO Robert Blum describes preparing for the potential commercial launch of aficamten, an upcoming monotherapy trial readout, omecamtiv mecarbil, and more | 01/16/25

19:05

SF Healthcare Week: Baird's Brian Skorney shares his take on this morning's conference news, the year ahead, and his top picks | 01/14/24

12:13

SF Healthcare Week: Flagship Pioneering's Noubar Afeyan on Moderna, gov't policy, China, and "polyintelligence" in drug development | 01/13/25

15:58

2025 SF Healthcare Week

ASCO25: Gilead Sciences Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more in the oncology pipeline | 05/31/25

15:21

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor | 06/01/25

09:08

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry | 05/30/25

19:01

ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news | 05/30/25

09:58

ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline | 05/31/25

08:29

ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation | 06/01/25

11:26

ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer | 06/01/25

11:00

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors | 06/01/25

12:14

#ASCO25

ApexOnco's Jacob Plieth shares his take on what to watch for at the 2024 ASH Annual meeting | 12/7/24

14:22

Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune) | 12/7/24

13:56

ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets | 12/8/24

13:29

Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

12:34

ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs | 12/7/24

09:41

ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company | 12/8/24

14:12

ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025 | 12/8/24

11:37

Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma | 12/7/24

06:43

#ASH24

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page